Close menu




October 20th, 2025 | 07:15 CEST

Almost 150% upside potential! Plug Power, Bayer, Planethic Group

  • Vegan
  • Food
  • Sustainability
  • Fuelcells
  • Pharma
  • bevtech
Photo credits: pixabay.com

Is Planethic Group (formerly Veganz Group) offering the buying opportunity of the fall? Analysts see over 100% upside potential. The recent correction appears exaggerated and could be an attractive entry point. The Company itself reports massive demand. Plug Power shares have performed strongly in recent months. Instead of taking profits, analysts see further upside — although some voices remain cautious, as the Company has promised to reach break-even many times before. And what do analysts say about Bayer? Very little at the moment. Goldman Sachs recommends the stock as a "Buy", but there is potential for a setback with the upcoming Q3 figures.

time to read: 3 minutes | Author: Fabian Lorenz
ISIN: PLUG POWER INC. DL-_01 | US72919P2020 , BAYER AG NA O.N. | DE000BAY0017 , PLANETHIC GROUP AG | DE000A3E5ED2

Table of contents:


    Planethic Group: Transformation offers over 100% upside potential

    Is Planethic Group (formerly Veganz Group) offering the buying opportunity of the fall? The stock was one of the turnaround stories of the first half of the year. Within a few months, it rose from EUR 5 to EUR 20. The correction since July came as no surprise, but its extent is surprising. However, at EUR 10.55, there is a great opportunity to buy or add to your position. In addition to the continued positive news flow, First Berlin has started coverage and the verdict is clear: "Buy", with a price target of EUR 26.

    Analysts see good reasons for the nearly 150% upside potential: The Berlin-based company is positioning itself this year as a "BevTech" pioneer with its proprietary 2D printing technology for dried, sliced, and packaged beverages. Initially, the Mililk® brand—a long-life, dried oat milk—is to be launched on the US market. Distribution agreements are already in place with Jindilli Beverages, a supplier to major chains such as Starbucks and McDonald's. If the ramp-up is successful, First Berlin expects Planethic to gain market share in the billion-dollar non-dairy category thanks to cost advantages and its sustainability profile. For 2027, analysts forecast an increase in revenue to EUR 117 million (2024: EUR 10.8 million) and an EBITDA margin of around 11%. Earnings per share are then expected to reach EUR 0.50 to the study.

    https://youtu.be/BSqBRGIHUm0?si=PjjG2CaJxMliDD4Y

    The estimates may even be too conservative. In its latest press release on its cooperation with the US group Vitiprints, Planethic emphasized that global demand for Mililk® is growing strongly and now exceeds 400 million liters per year. This means that the sales potential is likely to be well over EUR 200 million, especially since printed oat milk is only the beginning. The range is to be expanded to include other milk alternatives and juices.

    Plug Power: Another 50% increase in share price?

    Plug Power's share price is actually ripe for a correction. It has more than tripled in value within six months and is once again worth more than USD 4 billion on the stock market. However, the share price has remained stable so far, trading above USD 3. Even two surprises did not cause a sustained slide in the share price. Both the capital measure and the departure of the CEO had the potential to do so.

    According to analysts at TD Cowen, there is even more to come for Plug shares. After talks with management, the "Buy" recommendation was confirmed, and the price target was raised from USD 3 to USD 4.50. Management plausibly explained its plans for reaching profitability. Among other things, cost reductions, scaling, and price adjustments are expected to contribute to this. Plug Power sees short-term growth potential, particularly in the areas of electrolysers and material handling systems.

    However, the hydrogen pioneer is currently still burning through millions. It has therefore taken advantage of the share price increase and recently secured around USD 370 million in fresh capital through a warrant transaction.

    Not everyone sees Plug Power's future as so rosy. For example, Clear Street believes the Company still has a long way to go before it breaks even. Analysts consider the share price of USD 3.50 to be fairly valued and recently adjusted their recommendation from "Buy" to "Hold."

    Bayer: Analysts cautious

    And what do analysts say about Bayer shares? The Leverkusen-based company's shares have gained 38% in the current year, twice as much as the DAX.

    However, there have been remarkably few analyst comments in recent weeks. Goldman Sachs was the last to comment, slightly reducing its price target from EUR 35 to EUR 34.50. However, this was based solely on exchange rate changes. It is noteworthy that the analysts noted that their estimates for Bayer's third quarter are well below average expectations. EBITDA is 11% lower, and earnings per share are as much as 45% lower. If Goldman is right, there could be numerous negative comments when Bayer reports on the third quarter in November—an exact date has not yet been set.

    Overall, analysts are currently somewhat cautious about Bayer. According to marketscreener.com, 12 out of 19 analysts rate the pharmaceutical and agricultural group's stock as "Hold", seven experts recommend buying, with the average price target being EUR 28.50. Bayer shares are currently trading at EUR 26.80.


    The repositioning at Planethic Group is bearing fruit and should soon have a noticeable impact on sales and profits. In any case, the potential appears enormous, and analysts are also convinced. Plug Power appears to be winning back investors and analysts. However, there is still a long way to go before it breaks even. Bayer has already performed well. Buying the stock does not seem compelling at the moment.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Stefan Bode on September 21st, 2026 | 07:55 CEST

    Excitement In The Air: Amazon, Bilfinger, Generac and Power Metallic Mines

    • PGMs
    • Copper
    • Commodities
    • Industrial
    • Sustainability
    • AI

    On the stock market, it is not just financial metrics that matter, but also expectations and potential turning points in a company's story. A billion-dollar AI-related contract, a milestone in the commodities sector and a dramatic collapse in earnings show how quickly opportunities and risks can be reshuffled within days. It is precisely this mix of euphoria, hope and sharp setbacks that makes these three very different stocks so compelling right now – and provides investors with valuable clues as to where potential lies and where caution may be warranted.

    Read

    Commented by Armin Schulz on September 21st, 2026 | 07:30 CEST

    Novo Nordisk, BioNxt Solutions, Evotec: When Injections Become Pills, The Cash Starts Rolling In

    • Biotechnology
    • Biotech
    • Pharma
    • weightloss
    • ODF

    The daily injection has had its day. For a long time, taking biologics in pill form was considered a pipe dream, but as of this year, it is becoming a billion-dollar business. On September 17, 2026, Novo Nordisk announced a partnership with Orbis Medicines worth up to USD 1.4 billion to make injections available orally. In February, the Danish company secured a partnership with Vivtex worth up to USD 2.1 billion. Whoever can deliver peptides through the stomach could see the industry come knocking. We are taking a closer look at Novo Nordisk, BioNxt Solutions and Evotec, which cover the entire spectrum of this trend—from acquisitions to technology to development.

    Read

    Commented by Jens Castner on September 17th, 2026 | 08:50 CEST

    From Farm to Supermarket Shelf: MustGrow Biologics, Sprouts and Hain Celestial Fuel the Appetite for Organic

    • biologicals
    • agritech
    • biofertilizer
    • Organic
    • Food

    Created and Published on Behalf of MustGrow Biologics Corp.

    Healthy, sustainable, organic: the trend toward conscious eating shows no signs of slowing down. Yet the sector has recently disappointed on the stock market. Soaring costs for raw materials and logistics are eating into producers' margins, while inflation is forcing consumers to be more cautious at the checkout. But these lean years can also create opportunities. A closer look at the entire value chain, from the field to the supermarket shelf, reveals three very different cases: MustGrow Biologics, Hain Celestial and Sprouts Farmers Market. A comparison of the trio reveals where analysts see the greatest upside potential.

    Read